ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GB-115

Its studies are mostly in Anxiety Disorders · Adjustment Disorders, led by Valenta Pharm JSC.

Furthest: phase 4, since Feb 17, 20252 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSC21 open or runningphase 4since Feb 17, 2025Oct 14, 2022Dec 31, 2027phase 4 · NCT06843044

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2022First study: phase 3 study in Anxiety DisordersFirst studyNCT05586789 · 220 enrolled · Russian Federation
  2. Feb 17, 2025Phase 4 study in Anxiety DisordersNCT06843044 · 250 planned · Russia

Ahead

  1. Dec 31, 2027Primary completion: phase 4 study in Anxiety DisordersNCT06843044

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06843044Anxiety Disorders · Russia4RecruitingDec 31, 2027250
NCT05586789Anxiety Disorders · Russian Federation3CompletedNov 22, 2022220

How it is read

Names in the registry

  • “Ranquilon”, 2 entries

Codes read as this program: GB115.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.